Role of the QuantiFERON®-TB Gold In-Tube assay in screening new immigrants for tuberculosis infection

European Respiratory Journal

Volumn 40, Issue 6, 2012, Pages 1443-1449

  Mulder, Christiaan ^a,b   Van Deutekom, Henk ^c   Huisman, Erik M ^d   Toumanian, Sophie ^e   Koster, Ben F P J ^f   Meijer Veldman, Wieneke ^g   Van Loenhout Rooyackers, Joke H ^h   Appel, Milo ⁱ   Arend, Sandra M ^j   Borgdorff, Martien W ^b   Van Leth, Frank ^a,b  

^a KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c DEPARTMENT OF INFECTIOUS DISEASES   (Netherlands)

^d Public Health Service   (Netherlands)

^e Public Health Laboratory   (Netherlands)

^f Dept of Tuberculosis Control   (Netherlands)

^g Dept of Tuberculosis Control   (Netherlands)

^h Public Health Laboratories   (Netherlands)

ⁱ Public Health Service of Groningen   (Netherlands)

^j LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

Immigration; Latent tuberculosis; Screening; Tuberculosis

Indexed keywords

GAMMA INTERFERON;

ADULT; ARTICLE; BAYES THEOREM; COHORT ANALYSIS; DIAGNOSTIC TEST; DISEASE COURSE; FEMALE; HUMAN; IMMIGRANT; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PREVALENCE; PRIORITY JOURNAL; REGISTER; SCREENING TEST; SENSITIVITY ANALYSIS; TUBERCULOSIS; ADOLESCENT; COST BENEFIT ANALYSIS; DIAGNOSTIC KIT; INFECTION CONTROL; MASS SCREENING; METHODOLOGY; MICROBIOLOGY; MIGRATION; SENSITIVITY AND SPECIFICITY; TUBERCULIN TEST;

ADOLESCENT; ADULT; BAYES THEOREM; COHORT STUDIES; COMMUNICABLE DISEASE CONTROL; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; EMIGRANTS AND IMMIGRANTS; FEMALE; HUMANS; MALE; MASS SCREENING; NETHERLANDS; PREVALENCE; REAGENT KITS, DIAGNOSTIC; SENSITIVITY AND SPECIFICITY; TUBERCULIN TEST; TUBERCULOSIS;

EID: 84870633337     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00010612     Document Type: Article

References (31)

1. KNCV Tuberculosis Foundation. Tuberculose in Nederland 2009 [Tuberculosis in The Netherlands 2009]. KNCV Tuberculosis Foundation, The Hague, 2009.
2. van Leth F, Kalisvaart NA, Erkens CG, et al. Projection of the number of patients with tuberculosis in the Netherlands in 2030. Eur J Public Health 2009; 19: 424-427.
3. Bwire R, Nagelkerke N, Keizer ST, et al. Tuberculosis screening among immigrants in The Netherlands: what is its contribution to public health? Neth J Med 2000; 56: 63-71. (Pubitemid 30049136)
4. Erkens C, Slump E, Kamphorst M, et al. Coverage and yield of entry and follow-up screening for tuberculosis among new immigrants. Eur Respir J 2008; 32: 153-161.
5. Vos AM, Meima A, Verver S, et al. High incidence of pulmonary tuberculosis persists a decade after immigration, The Netherlands. Emerg Infect Dis 2004; 10: 736-739. (Pubitemid 38420314)
6. Ricks PM, Cain KP, Oeltmann JE, et al. Estimating the burden of tuberculosis among foreign-born persons acquired prior to entering the U.S., 2005-2009. PLoS One 2011; 6: e27405.
7. Menzies D, Al Jahdali H, Al Otaibi B. Recent developments in treatment of latent tuberculosis infection. Indian J Med Res 2011; 133: 257-266.
8. Borgdorff MW, van den Hof S, Kremer K, et al. Progress towards tuberculosis elimination: secular trend, immigration and transmission. Eur Respir J 2010; 36: 339-347.
9. Pai M, Dheda K, Cunningham J, Scano F, et al. T-cell assays for the diagnosis of latent tuberculosis infection: moving the research agenda forward. Lancet Infect Dis 2007; 7: 428-438. (Pubitemid 46779096)
10. Rangaka MX, Wilkinson KA, Glynn JR, et al. Predictive value of interferon-c release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12: 45-55.
11. Oxlade O, Schwartzman K, Menzies D. Interferon-c release assays and TB screening in high-income countries: a cost-effectiveness analysis. Int J Tuberc Lung Dis 2007; 11: 16-26. (Pubitemid 46101841)
12. Diel R, Loddenkemper R, Meywald-Walter K, et al. Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med 2008; 177: 1164-1170. (Pubitemid 351717577)
13. Kik SV, Franken WP, Mensen M, et al. Predictive value for progression to tuberculosis by IGRA and TST in immigrant contacts. Eur Respir J 2010; 35: 1346-1353.
14. Yoshiyama T, HaradaN,Higuchi K, et al. Use of the QuantiFERON-TB Gold test for screening tuberculosis contacts and predicting active disease. Int J Tuberc Lung Dis 2010; 14: 819-827.
15. Diel R, Loddenkemper R, Niemann S, et al. Negative and positive predictive value of a whole-blood interferon-c release assay for developing active tuberculosis: an update. Am J Respir Crit Care Med 2011; 183: 88-95.
16. Aichelburg MC, Rieger A, Breitenecker F, et al. Detection and prediction of active tuberculosis disease by a whole-blood interferon-c release assay in HIV-1-infected individuals. Clin Infect Dis 2009; 48: 954-962.
17. Mahomed H, Hawkridge T, Verver S, et al. The tuberculin skin test versus QuantiFERON TB Gold1 in predicting tuberculosis disease in an adolescent cohort study in South Africa. PLoS One 2011; 6: e17984.
18. Harstad I, Winje BA, Heldal E, et al. Predictive values of QuantiFERON-TB Gold testing in screening for tuberculosis disease in asylum seekers. Int J Tuberc Lung Dis 2010; 14: 1209-1211.
19. Ntzoufras I. Basyesian Modeling Using WinBUGS. New York, Wiley, 2009.
20. Pareek M, Watson JP, Ormerod LP, et al. Screening of immigrants in the UK for imported latent tuberculosis: a multicentre cohort study and cost-effectiveness analysis. Lancet Infect Dis 2011; 11: 435-444.
21. Wilson JMG, Jungner G. Principles and Practice of Screening for Disease. Geneva, World Health Organization, 1968.
22. Coker R, van Weezenbeek KL. Mandatory screening and treatment of immigrants for latent tuberculosis in the USA: just restraint? Lancet Infect Dis 2001; 1: 270-276.
23. Borgdorff MW, Sebek M, Geskus RB, et al. The incubation period distribution of tuberculosis estimated with a molecular epidemiological approach. Int J Epidemiol 2011; 40: 964-970.
24. Goletti D, Butera O, Vanini V, et al. Response to Rv2628 latency antigen associates with cured tuberculosis and remote infection. Eur Respir J 2010; 36: 135-142.
25. Ena J, Valls V. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. Clin Infect Dis 2005; 40: 670-676. (Pubitemid 40381339)
26. Kunst H, Khan KS. Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review. Int J Tuberc Lung Dis 2010; 14: 1374-1381.
27. Mulder C, Erkens CG, Kouw PM, et al. Missed opportunities in tuberculosis control in The Netherlands due to prioritization of contact investigations. Eur J Public Health 2012; 22: 177-182.
28. Mulder C, van Deutekom H, Huisman EM, et al. Coverage and yield of tuberculosis contact investigations in the Netherlands. Int J Tuberc Lung Dis 2011; 15: 1630-1637.
29. Grinsdale JA, Ho CS, Banouvong H, et al. Programmatic impact of using QuantiFERON®-TB Gold in routine contact investigation activities. Int J Tuberc Lung Dis 2011; 15: 1614-1620.
30. van Leth F, Borgdorff M. Contact tracing in low-incidence tuberculosis settings. Int J Tuberc Lung Dis 2011; 15: 1566.
31. Bakir M, Millington KA, Soysal A, et al. Prognostic value of a T-cell-based, interferon-c biomarker in children with tuberculosis contact. Ann Intern Med 2008; 149: 777-787.